Novartis
↗Basel, Switzerland
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland, created in March 1996 from the merger of Ciba-Geigy and Sandoz Laboratories. The company is one of the world's largest pharmaceutical companies by revenue and operates in approximately 140 countries. Novartis was restructured in 2023 with the spinoff of its generics division (Sandoz) to focus on innovative medicines through its Innovative Medicines division. The company operates across five therapeutic modalities including traditional chemistry, biotherapeutics, xRNA, radioligand therapy, and gene and cell therapies, with major therapeutic areas in oncology, immunology, cardiovascular-renal-metabolic diseases, neuroscience, and rare diseases.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Innovative medicines, oncology, immunology, gene therapy, rare disease
SIZE & FINANCIALS
Employees:10000+
Revenue:$51.72B (2024)
Founded:1996
Ownership:public
Status:operating
STOCK
Exchange:NYSE, SWX (Swiss Exchange)
Ticker:NVS
Market Cap:$253.58B
PIPELINE
Stage:Phase 2, Phase 3, Commercial
Lead Drug Stage:Phase 3 - Multiple late-stage programs
Modalities:Small molecule, mAb (monoclonal antibodies), Cell therapy (CAR-T), Gene therapy (AAV-based, intrathecal), Radioligand therapy, xRNA, Protein therapeutics
Active Trials:4000
Trial Phases:-
FDA Approvals:4
CORPORATE STRUCTURE
Subsidiaries:Novartis Gene Therapies, Novartis Institutes for Biomedical Research (NIBR)
Key Partnerships:Avidity Biosciences (RNA therapeutics) - $12B acquisition (pending, H1 2026), Schrödinger (AI-powered drug discovery) - $150M upfront + up to $892M in milestones, Monte Rosa Therapeutics (molecular glue degraders) - $120M upfront + up to $5.7B in milestones, Generate:Biomedicines (protein therapeutics) - $65M upfront, Isomorphic Labs (AI-driven drug discovery) - partnership valued ~$3B, Ratio Therapeutics (radiotherapeutics) - exclusive license agreement, Anthos Therapeutics (cardiovascular) - $925M acquisition (pending, H1 2025), Regulus Therapeutics (siRNA therapeutics) - $1.7B deal, Tourmaline Bio (cardiovascular) - $1.4B deal
COMPETITION
Position:Leader
Competitors:Roche (Genentech), Pfizer, Merck, Johnson & Johnson (Janssen), Bristol Myers Squibb, AstraZeneca, Gilead Sciences, Eli Lilly
LEADERSHIP
Key Executives:
Vasant Narasimhan - Chief Executive Officer (CEO)
Giovanni Caforio - Chair of the Board
Shreeram Aradhye - Executive Committee Member
Karen L. Hale - Executive Committee Member
Fiona H. Marshall - Executive Committee Member
Scientific Founders:Ciba-Geigy (merged to form Novartis, 1996), Sandoz Laboratories (merged to form Novartis, 1996)
Board Members:Giovanni Caforio (Chair), Vasant Narasimhan (CEO), Simon Moroney (Chair, Compensation Committee), 11 additional board members
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Novartis. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.